Building a true partnership with patients has shown to gain trust and improve patient outcomes(http://bit.ly/31kCu4X). But knowing how to do this can be a challenge for many patient-centric leaders. Which is why eyeforpharma has pulled together 4 case studies from #Astrazeneca, #Takeda and #Novartis http://bit.ly/31kCu4X to show you how to deliver patient-centered outcomes through partnerships.
Access these 4 case studies – including slides and audio here: http://bit.ly/31kCu4X

https://t.co/DvWzq1lA46

See how big pharma are scaling and measuring patient centricity with Novartis, Janssen and Bayer.
Free copy available here: http://bit.ly/2PkqXMB

#patientcentricity #precisionmedicine #bigpharma #medical #healthcare #pharmaceutical

Patient-centered care is often referred to in the context of traditional healthcare, but scientists at MedImmune will tell you: Focusing on improving the patient journey – from earlier diagnosis to integrated and/or targeted assessment – is, and has been, a top priority.

MedImmune isn’t alone. Much of the biotech industry is shifting away from the “one-​size-​fit-​all” approach to drug development, and a patient centric paradigm is emerging ­– notably with the rise of data collected from non-traditional methods in the real-world setting and better ways to analyze that data.

But exactly how are digital technologies transforming this new paradigm, particularly patients’ and drug developers’ understanding of diseases and treatment options?

On October 9, 2018, MedImmune hosted a one-​​day Translational Science Forum in the Bay Area, gathering academic institutions, industry leaders, and other experts in the drug development ecosystem to assess this critical question.

If you missed the event, here’s the top takeaways and findings from a roster of expert speakers:

https://lnkd.in/gwfRsia